Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Roche's Diagnostic Foothold Gives Genentech A Leg Up In Oncology

This article was originally published in The Pink Sheet Daily

Executive Summary

Research to be presented at American Society of Clinical Oncology meeting shows role of biomarkers for lead compounds, including vemurafenib, MetMAb and Tarceva.

You may also be interested in...



Roche Could Repeat Genentech Success With Foundation Medicine Partnership

Foundation Medicine gets a $400 million cash infusion to continue its cancer diagnostic R&D while Roche acquires a majority interest in the company and will use its products to guide and optimize its clinical trials for cancer immunotherapies.

Roche’s Onartuzumab Failure Raises More Questions About How Best To Target Met

Roche’s onartuzumab (MetMab) fails in Phase III lung cancer study, raising questions about the company’s biomarker approach and the Met target more generally.

Roche’s Onartuzumab Failure Raises More Questions About How Best To Target Met

Roche’s onartuzumab (MetMab) fails in Phase III lung cancer study, raising questions about the company’s biomarker approach and the Met target more generally.

Related Content

Topics

UsernamePublicRestriction

Register

PS072389

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel